阿里健康(00241.HK):Undervalued potential “New Healthcare“ champion, initiate with BUY and SOTP-based TP of HK$6.8

6 年前3.9k
机构:招商证券评级:买入目标价:6.8港元■ Ali Health has evolved into a healthcare informatics propelled, integrated healthcare e-commerce

机构:招商证券

评级:买入

目标价:6.8港元

■ Ali Health has evolved into a healthcare informatics propelled, integrated healthcare e-commerce and service platform in China to ride the “Internet + Healthcare” policy tailwind 

■ We expect Co. to have 62% CAGR in revenue over FY19-22E (Mar YE), and to continue to have positive adj. NP, reflecting its leading and growing market share in ecommerce, rising contribution from innovative revenue, synergy with online healthcare, protected by continuously strong investment in HCIT 

■ Company currently trades at FY21 EV/Sales 3.9x vs listed peer’s 5.2x; initiate with BUY and SOTP-based TP of HK$6.8 

China’s healthcare e-commerce champion 

From a data tracking service company, Ali Health evolved into a healthcare e-commerce champion. Though China’s health product ecommerce GMV reached c.RMB100bn in 2017, its penetration rate (3%) remains low vs the overall e-commerce (20%). Co.’s own B2C unit (65% of FY18 GP) has solid No.1 position in online pharmacies. Its parent’s Tmall Medicine Hall (from which Co. derives 19% of its GP) was also the leader in online marketplace. As such, Co. should benefit significantly from the rising e-commerce penetration and upcoming RX pharma deregulation. 

Riding the wave of “Internet + Healthcare” 

We estimate a new RMB13bn “Internet healthcare” market is in the making by 2020E, thanks to China’s “Internet+” initiatives and advancing technologies. Different from peers who primarily focus on online consultation, Co. is exploring various online/offline scenarios to help hospitals in areas from early diagnosis to clinical supports, leveraging its strength in healthcare informatics (Big Data/Cloud/AI). Given time, we think it can replicate its success with pharmacies and build out a “Tmall for hospitals”. 

We arrived at SOTP valuation of HK$6.8 

Our SOTP TP applies FY22 EV/EBITDA for e-commerce and FY22 EV/Sale for advertising & marketing and discounted them back to end FY19. We refrained from directly valuing its internet healthcare business as the monetisation remains remote and peers’ metrics are not comparable. Instead we capitalised 2/3 of the R&D spend (i.e. that of HCIT) over FY19-22E and applied a P/B valuation for such assets, as we view them as necessary investment for Ali Health’s future as a “New Healthcare” champion. 

image.png

相关股票

HK 阿里健康

格隆汇声明:文中观点均来自原作者,不代表格隆汇观点及立场。特别提醒,投资决策需建立在独立思考之上,本文内容仅供参考,不作为实际操作建议,交易风险自担。

App内直接打开
商务、渠道、广告合作/招聘立即咨询

相关文章

美团2023Q4经调整净利增超4倍,盘中大涨超8%,中概互联ETF(513220)上周五获资金净流入超500万元

· 03-25 10:54

cover_pic

港股反弹一日游,恒生地产和恒生科技大幅跳水,可以抄底了吗?

· 03-23 15:54

cover_pic

新零售泡沫破灭,马云“坑惨”兄弟们

· 03-21 22:04

cover_pic
我也说两句
手机号码
+86
验证码
* 微信登录请先绑定手机号,绑定后可通过手机号在APP/网站登录。
绑定

绑定失败

该手机号已注册格隆汇账号,您可以选择合并账号。

关于合并:

1.合并后可使用手机号或微信快捷登录;

2.仅保留手机账号信息,清除原有微信账号信息;

3.付费权益将同步至手机账号;

4.部分特殊情形可能导致无法合并;

合并
返回上一步
确认您合并的手机号
获取验证码输入后提交合并账号
合并